Loading...

Pieris Pharmaceuticals

Nasdaq:PIRS
Snowflake Description

Flawless balance sheet and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PIRS
Nasdaq
$214M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The last earnings update was 39 days ago. More info.


Add to Portfolio Compare Print
  • Pieris Pharmaceuticals has significant price volatility in the past 3 months.
PIRS Share Price and Events
7 Day Returns
3.8%
NasdaqCM:PIRS
-0.4%
US Biotechs
0.3%
US Market
1 Year Returns
-14%
NasdaqCM:PIRS
-9%
US Biotechs
0.7%
US Market
PIRS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Pieris Pharmaceuticals (PIRS) 3.8% 21.2% 34.3% -14% 163.6% -
US Biotechs -0.4% -1% -8.9% -9% 11.4% 5.1%
US Market 0.3% 0.4% 0.6% 0.7% 37.2% 37.4%
1 Year Return vs Industry and Market
  • PIRS underperformed the Biotechs industry which returned -9% over the past year.
  • PIRS underperformed the Market in United States of America which returned 0.7% over the past year.
Price Volatility
PIRS
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Pieris Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Pieris Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Pieris Pharmaceuticals.

NasdaqCM:PIRS Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqCM:PIRS
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.32
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.318 (1 + (1- 21%) (0%))
1.213
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.21
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.213 * 5.96%)
9.96%

Discounted Cash Flow Calculation for NasdaqCM:PIRS using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Pieris Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqCM:PIRS DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 9.96%)
2019 -34.90 Analyst x1 -31.74
2020 -43.65 Analyst x2 -36.10
2021 -33.60 Analyst x2 -25.27
2022 -65.20 Analyst x1 -44.60
2023 63.00 Analyst x1 39.19
2024 88.29 Est @ 40.14% 49.95
2025 113.82 Est @ 28.92% 58.56
2026 137.80 Est @ 21.06% 64.47
2027 159.24 Est @ 15.56% 67.75
2028 177.89 Est @ 11.71% 68.83
Present value of next 10 years cash flows $211.04
NasdaqCM:PIRS DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $177.89 × (1 + 2.73%) ÷ (9.96% – 2.73%)
$2,527.58
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,527.58 ÷ (1 + 9.96%)10
$978.02
NasdaqCM:PIRS Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $211.04 + $978.02
$1,189.06
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,189.06 / 49.17
$24.18
NasdaqCM:PIRS Discount to Share Price
Calculation Result
Value per share (USD) From above. $24.18
Current discount Discount to share price of $4.35
= -1 x ($4.35 - $24.18) / $24.18
82%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Pieris Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is $4.35 vs Future cash flow value of $24.18
Current Discount Checks
For Pieris Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Pieris Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Pieris Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Pieris Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Pieris Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:PIRS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.53
NasdaqCM:PIRS Share Price ** NasdaqCM (2019-06-17) in USD $4.35
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.23x
United States of America Market PE Ratio Median Figure of 3,093 Publicly-Listed Companies 17.68x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Pieris Pharmaceuticals.

NasdaqCM:PIRS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:PIRS Share Price ÷ EPS (both in USD)

= 4.35 ÷ -0.53

-8.17x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pieris Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.
  • Pieris Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Pieris Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqCM:PIRS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -8.17x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
-6.6%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 1.08x
United States of America Market PEG Ratio Median Figure of 2,125 Publicly-Listed Companies 1.52x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Pieris Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Pieris Pharmaceuticals's assets?
Raw Data
NasdaqCM:PIRS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.61
NasdaqCM:PIRS Share Price * NasdaqCM (2019-06-17) in USD $4.35
United States of America Biotechs Industry PB Ratio Median Figure of 425 Publicly-Listed Biotechs Companies 2.9x
United States of America Market PB Ratio Median Figure of 5,245 Publicly-Listed Companies 1.79x
NasdaqCM:PIRS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:PIRS Share Price ÷ Book Value per Share (both in USD)

= 4.35 ÷ 0.61

7.09x

* Primary Listing of Pieris Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pieris Pharmaceuticals is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Pieris Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Pieris Pharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Pieris Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-6.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Pieris Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Pieris Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Pieris Pharmaceuticals's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Pieris Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:PIRS Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:PIRS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts -6.6%
NasdaqCM:PIRS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 27%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.8%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:PIRS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:PIRS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 98 -22 3
2022-12-31 37 -105 4
2021-12-31 28 -73 4
2020-12-31 27 -57 5
2019-12-31 33 -41 3
NasdaqCM:PIRS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 33 -48 -28
2018-12-31 29 -1 -27
2018-09-30 42 3 -8
2018-06-30 38 53 -8
2018-03-31 28 55 -18
2017-12-31 25 50 -18
2017-09-30 10 48 -32
2017-06-30 7 9 -31
2017-03-31 6 9 -27
2016-12-31 6 -14 -23
2016-09-30 5 -10 -19
2016-06-30 5 -10 -17

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Pieris Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Pieris Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:PIRS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Pieris Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:PIRS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.32 0.39 -1.40 3.00
2022-12-31 -1.68 -1.33 -2.33 3.00
2021-12-31 -1.20 -0.25 -2.24 4.00
2020-12-31 -0.99 -0.58 -1.37 5.00
2019-12-31 -0.79 -0.73 -0.85 4.00
NasdaqCM:PIRS Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.53
2018-12-31 -0.50
2018-09-30 -0.15
2018-06-30 -0.18
2018-03-31 -0.40
2017-12-31 -0.40
2017-09-30 -0.73
2017-06-30 -0.71
2017-03-31 -0.63
2016-12-31 -0.55
2016-09-30 -0.47
2016-06-30 -0.42

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Pieris Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Pieris Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Pieris Pharmaceuticals has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Pieris Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Pieris Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Pieris Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Pieris Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Pieris Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Pieris Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Pieris Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:PIRS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 33.49 -28.39 19.52 47.35
2018-12-31 29.10 -26.75 18.94 40.99
2018-09-30 42.34 -7.58 20.77 33.26
2018-06-30 37.92 -8.49 18.88 28.12
2018-03-31 28.08 -18.37 18.45 24.36
2017-12-31 25.28 -17.65 18.08 21.79
2017-09-30 9.85 -31.70 13.90 23.43
2017-06-30 6.71 -30.83 13.39 21.80
2017-03-31 5.93 -26.63 11.41 20.90
2016-12-31 5.83 -22.80 9.39 19.20
2016-09-30 5.24 -19.14 8.86 15.31
2016-06-30 4.87 -16.87 8.76 12.74
2016-03-31 3.96 -14.51 8.36 9.96
2015-12-31 2.93 -14.06 8.79 7.83
2015-09-30 4.07 -15.32 9.77 7.33
2015-06-30 3.67 -13.42 8.46 6.21
2015-03-31 4.21 -12.77 8.84 5.60
2014-12-31 5.37 -9.85 7.26 5.30
2014-09-30 5.52 -4.78 4.88 4.90
2013-12-31 12.43 0.07 2.68 9.19
2012-12-31 11.38 -2.32 2.99 10.57

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Pieris Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Pieris Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Pieris Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Pieris Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Pieris Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Pieris Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Pieris Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Pieris Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Pieris Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Pieris Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Pieris Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Pieris Pharmaceuticals Company Filings, last reported 2 months ago.

NasdaqCM:PIRS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 30.16 0.00 110.78
2018-12-31 39.94 0.00 128.11
2018-09-30 50.26 0.00 137.30
2018-06-30 55.32 0.00 150.98
2018-03-31 50.69 0.00 159.58
2017-12-31 11.52 0.00 72.63
2017-09-30 4.56 0.00 89.92
2017-06-30 9.33 0.00 50.33
2017-03-31 18.04 0.00 55.24
2016-12-31 25.23 0.00 29.36
2016-09-30 31.48 0.00 36.56
2016-06-30 37.29 0.00 40.37
2016-03-31 27.18 0.00 31.19
2015-12-31 31.13 0.00 29.35
2015-09-30 33.65 0.00 32.25
2015-06-30 11.15 0.00 10.03
2015-03-31 14.23 0.00 13.17
2014-12-31 18.01 1.27 18.47
2014-09-30 -3.51 5.74 0.94
2013-12-31 0.59 4.75 3.69
2012-12-31 0.50 3.82 6.33
  • Pieris Pharmaceuticals has no debt.
  • Pieris Pharmaceuticals currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Pieris Pharmaceuticals has sufficient cash runway for 2.3 years based on current free cash flow.
  • Pieris Pharmaceuticals has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of -15.4% each year.
X
Financial health checks
We assess Pieris Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Pieris Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Pieris Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Pieris Pharmaceuticals dividends.
If you bought $2,000 of Pieris Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Pieris Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Pieris Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:PIRS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2011 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:PIRS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Pieris Pharmaceuticals has not reported any payouts.
  • Unable to verify if Pieris Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Pieris Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Pieris Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Pieris Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Pieris Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Pieris Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Pieris Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Steve Yoder
COMPENSATION $2,621,008
AGE 42
TENURE AS CEO 4.5 years
CEO Bio

Mr. Stephen S. Yoder, also known as Steve, J.D., has been the Chief Executive Officer and President at Pieris Pharmaceuticals, Inc. since December 17, 2014. Mr. Yoder joined Pieris Pharmaceuticals GmbH as Chief Executive Officer in January 2010. Mr. Yoder served as Chief Executive Officer of Pieris Operating from January 04, 2010 to December 17, 2014. From July 2003 to December 2010 he led the intellectual property and legal departments at MorphoSys AG, a biotechnology company involved in the development and research of antibodies, as General Counsel. From September 1999 to June 2003, he worked in several Washington, D.C. law firms, specializing in a life sciences intellectual property practice. He has been a Director of Pieris Pharmaceuticals, Inc. since December 17,2014. As an attorney, he is licensed to practice before the United States Patent and Trademark Office, and in the jurisdictions of Maryland and Washington, D.C. Mr. Yoder holds degrees in molecular biology and Spanish from Grove City College and a Juris Doctorate, with honors, from The George Washington University Law School.

CEO Compensation
  • Steve's compensation has increased whilst company is loss making.
  • Steve's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Pieris Pharmaceuticals management team in years:

2
Average Tenure
43
Average Age
  • The average tenure for the Pieris Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Steve Yoder

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
42
TENURE
4.5 yrs

Allan Reine

TITLE
Senior VP
COMPENSATION
$871K
AGE
43
TENURE
1.8 yrs

Louis Matis

TITLE
Senior VP & Chief Development Officer
COMPENSATION
$1M
AGE
67
TENURE
3.8 yrs

Claus Schalper

TITLE
Co-Founder & Senior Advisor
TENURE
1.8 yrs

Maria Kelman

TITLE
Director of Investor Relations

Ahmed Mousa

TITLE
VP, General Counsel & Corporate Secretary
TENURE
2.1 yrs

Frank Vollmering

TITLE
Vice President of Human Resources
TENURE
1.4 yrs

Christine Rothe

TITLE
Head of Discovery & Alliance Management and VP

Shane Olwill

TITLE
Head of Development & Immuno-Oncology and VP

Eckhard Niemeier

TITLE
VP & Head of Business Development
Board of Directors Tenure

Average tenure and age of the Pieris Pharmaceuticals board of directors in years:

2.8
Average Tenure
61
Average Age
  • The average tenure for the Pieris Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Jim Geraghty

TITLE
Chairman
COMPENSATION
$200K
AGE
63
TENURE
1.5 yrs

Steve Yoder

TITLE
CEO, President & Director
COMPENSATION
$3M
AGE
42
TENURE
4.5 yrs

Steve Prelack

TITLE
Director
COMPENSATION
$150K
AGE
61
TENURE
4.5 yrs

Chris Kiritsy

TITLE
Director
COMPENSATION
$153K
AGE
53
TENURE
2.8 yrs

Peter Kiener

TITLE
Director
COMPENSATION
$106K
AGE
66
TENURE
0.8 yrs

Michael Richman

TITLE
Director
COMPENSATION
$144K
AGE
57
TENURE
4.5 yrs

Jean-Pierre Bizzari

TITLE
Director
COMPENSATION
$140K
AGE
64
TENURE
4.1 yrs

Ann Barbier

TITLE
Director
COMPENSATION
$154K
AGE
54
TENURE
1.2 yrs

Matt Sherman

TITLE
Director
COMPENSATION
$100K
AGE
62
TENURE
0.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
27. Sep 18 Sell OrbiMed Advisors, L.L.C. Company 07. Jul 18 25. Sep 18 -684,100 $5.79 $-3,753,512
17. Sep 18 Buy Christopher Kiritsy Individual 14. Sep 18 14. Sep 18 5,000 $5.11 $25,525
22. Jun 18 Sell OrbiMed Advisors, L.L.C. Company 08. Jun 18 20. Jun 18 -810,000 $5.70 $-4,442,200
X
Management checks
We assess Pieris Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Pieris Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Investors Who Bought Pieris Pharmaceuticals (NASDAQ:PIRS) Shares A Year Ago Are Now Down 54%

During that time the share price has sank like a stone, descending 54%. … Pieris Pharmaceuticals isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … Pieris Pharmaceuticals grew its revenue by 15% over the last year.

Simply Wall St -

Is Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) A Volatile Stock?

Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

Is Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) CEO Being Overpaid?

In 2014 Steve Yoder was appointed CEO of Pieris Pharmaceuticals, Inc. … This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. … How Does Steve Yoder's Compensation Compare With Similar Sized Companies?

Simply Wall St -

What Kind Of Shareholders Own Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)?

The big shareholder groups in Pieris Pharmaceuticals, Inc. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Companies that have been privatized tend to have low insider ownership.

Simply Wall St -

What Investors Should Know About Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Financial Strength

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Does PIRS's growth rate justify its decision for financial flexibility over lower cost of capital. … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital

Simply Wall St -

Should You Take Comfort From Insider Transactions At Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)?

So we'll take a look at whether insiders have been buying or selling shares in Pieris Pharmaceuticals, Inc. … That means that an insider was happy to buy shares at above the current price. … We generally consider it a positive if insiders have been buying on market, even above the current price.

Simply Wall St -

How Does Investing In Pieris Pharmaceuticals Inc (NASDAQ:PIRS) Impact The Volatility Of Your Portfolio?

If you're interested in Pieris Pharmaceuticals Inc (NASDAQ:PIRS), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

What Kind Of Shareholder Appears On The Pieris Pharmaceuticals Inc's (NASDAQ:PIRS) Shareholder Register?

Conversely, insiders often decrease their ownership over time. … We also tend to see lower insider ownership in companies that were previously publicly owned. … Taking a look at the our data on the ownership groups (below), it's seems that.

Simply Wall St -

Is Pieris Pharmaceuticals Inc's (NASDAQ:PIRS) CEO Pay Justified?

Leading Pieris Pharmaceuticals Inc (NASDAQ:PIRS) as the CEO, Steve Yoder took the company to a valuation of US$275.04m. … Understanding how CEOs are incentivised to run and grow their company is an important aspect of investing in a stock. … CEOs leading companies of similar size and profitability

Simply Wall St -

How Pieris Pharmaceuticals Inc (NASDAQ:PIRS) Can Impact Your Portfolio Volatility

Generally, an investor should consider two types of risk that impact the market value of PIRS. … The other type of risk, which cannot be diversified away, is market risk. … A widely-used metric to measure a stock's market risk is beta, and the broad market index represents a beta value of one.

Simply Wall St -

Company Info

Description

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. Its lead respiratory program includes PRS-060, a drug candidate, which is in Phase I clinical trial that binds to IL-4Ra for the treatment of asthma and other inflammatory diseases; and lead immuno-oncology program comprises PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases. The company is also developing PRS-344, a bispecific anticalin-antibody fusion protein that is in preclinical stage for oncology diseases; and PRS-080, a polyethylene glycol conjugated anticalin protein that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc., as well as others; and non-strategic license or option agreements with Aska Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc., and Sanofi, as well as license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Details
Name: Pieris Pharmaceuticals, Inc.
PIRS
Exchange: NasdaqCM
Founded:
$213,902,958
49,173,094
Website: http://www.pieris.com
Address: Pieris Pharmaceuticals, Inc.
255 State Street,
9th Floor,
Boston,
Massachusetts, 02109,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM PIRS New Common Stock Nasdaq Capital Market US USD 18. Dec 2014
DB PI6 New Common Stock Deutsche Boerse AG DE EUR 18. Dec 2014
Number of employees
Current staff
Staff numbers
112
Pieris Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/18 00:37
End of day share price update: 2019/06/17 00:00
Last estimates confirmation: 2019/05/23
Last earnings filing: 2019/05/10
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.